Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Alterations in brain neurocircuitry following treatment with the chemotherapeutic agent paclitaxel in rats.

Ferris CF, Nodine S, Pottala T, Cai X, Knox TM, Fofana FH, Kim S, Kulkarni P, Crystal JD, Hohmann AG.

Neurobiol Pain. 2019 May 27;6:100034. doi: 10.1016/j.ynpai.2019.100034. eCollection 2019 Aug-Dec.

3.

NCI Clinical Trials Planning Meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy.

Dorsey SG, Kleckner IR, Barton D, Mustian K, O'Mara A, St Germain D, Cavaletti G, Danhauer SC, Hershman D, Hohmann AG, Hoke A, Hopkins JO, Kelly KP, Loprinzi CL, McLeod HL, Mohile S, Paice J, Rowland JH, Salvemini D, Segal RA, Lavoie Smith E, McCaskill Stevens W, Janelsins MC.

J Natl Cancer Inst. 2019 Jan 31. doi: 10.1093/jnci/djz011. [Epub ahead of print]

PMID:
30715378
4.

Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal.

Li AL, Lin X, Dhopeshwarkar AS, Thomaz AC, Carey LM, Liu Y, Nikas SP, Makriyannis A, Mackie K, Hohmann AG.

Mol Pharmacol. 2019 Feb;95(2):155-168. doi: 10.1124/mol.118.113233. Epub 2018 Nov 30.

PMID:
30504240
5.

Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.

Slivicki RA, Saberi SA, Iyer V, Vemuri VK, Makriyannis A, Hohmann AG.

J Pharmacol Exp Ther. 2018 Dec;367(3):551-563. doi: 10.1124/jpet.118.252288. Epub 2018 Oct 1.

PMID:
30275151
6.

( R)- N-(1-Methyl-2-hydroxyethyl)-13-( S)-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes.

Liu Y, Ji L, Eno M, Kudalkar S, Li AL, Schimpgen M, Benchama O, Morales P, Xu S, Hurst D, Wu S, Mohammad KA, Wood JT, Zvonok N, Papahatjis DP, Zhou H, Honrao C, Mackie K, Reggio P, Hohmann AG, Marnett LJ, Makriyannis A, Nikas SP.

J Med Chem. 2018 Oct 11;61(19):8639-8657. doi: 10.1021/acs.jmedchem.8b00611. Epub 2018 Sep 21.

PMID:
30196704
7.

ZLc002, a putative small-molecule inhibitor of nNOS interaction with NOS1AP, suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with paclitaxel to reduce tumor cell viability.

Lee WH, Carey LM, Li LL, Xu Z, Lai YY, Courtney MJ, Hohmann AG.

Mol Pain. 2018 Jan-Dec;14:1744806918801224. doi: 10.1177/1744806918801224. Epub 2018 Aug 29.

8.

Replay of Episodic Memories in the Rat.

Panoz-Brown D, Iyer V, Carey LM, Sluka CM, Rajic G, Kestenman J, Gentry M, Brotheridge S, Somekh I, Corbin HE, Tucker KG, Almeida B, Hex SB, Garcia KD, Hohmann AG, Crystal JD.

Curr Biol. 2018 May 21;28(10):1628-1634.e7. doi: 10.1016/j.cub.2018.04.006. Epub 2018 May 10.

9.

Disruption of nNOS-NOS1AP protein-protein interactions suppresses neuropathic pain in mice.

Lee WH, Li LL, Chawla A, Hudmon A, Lai YY, Courtney MJ, Hohmann AG.

Pain. 2018 May;159(5):849-863. doi: 10.1097/j.pain.0000000000001152.

10.

Slowly Signaling G Protein-Biased CB2 Cannabinoid Receptor Agonist LY2828360 Suppresses Neuropathic Pain with Sustained Efficacy and Attenuates Morphine Tolerance and Dependence.

Lin X, Dhopeshwarkar AS, Huibregtse M, Mackie K, Hohmann AG.

Mol Pharmacol. 2018 Feb;93(2):49-62. doi: 10.1124/mol.117.109355. Epub 2017 Nov 30.

11.

Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence.

Slivicki RA, Xu Z, Kulkarni PM, Pertwee RG, Mackie K, Thakur GA, Hohmann AG.

Biol Psychiatry. 2018 Nov 15;84(10):722-733. doi: 10.1016/j.biopsych.2017.06.032. Epub 2017 Jul 8.

12.

The chemotherapeutic agent paclitaxel selectively impairs reversal learning while sparing prior learning, new learning and episodic memory.

Panoz-Brown D, Carey LM, Smith AE, Gentry M, Sluka CM, Corbin HE, Wu JE, Hohmann AG, Crystal JD.

Neurobiol Learn Mem. 2017 Oct;144:259-270. doi: 10.1016/j.nlm.2017.08.001. Epub 2017 Aug 12.

13.

The cannabinoid system and pain.

Woodhams SG, Chapman V, Finn DP, Hohmann AG, Neugebauer V.

Neuropharmacology. 2017 Sep 15;124:105-120. doi: 10.1016/j.neuropharm.2017.06.015. Epub 2017 Jun 15. Review.

14.

Cannabinoid CB2 Agonist GW405833 Suppresses Inflammatory and Neuropathic Pain through a CB1 Mechanism that is Independent of CB2 Receptors in Mice.

Li AL, Carey LM, Mackie K, Hohmann AG.

J Pharmacol Exp Ther. 2017 Aug;362(2):296-305. doi: 10.1124/jpet.117.241901. Epub 2017 Jun 7.

15.

Inflammatory and Neuropathic Nociception is Preserved in GPR55 Knockout Mice.

Carey LM, Gutierrez T, Deng L, Lee WH, Mackie K, Hohmann AG.

Sci Rep. 2017 Apr 20;7(1):944. doi: 10.1038/s41598-017-01062-2.

16.

Small molecule inhibitors of PSD95-nNOS protein-protein interactions suppress formalin-evoked Fos protein expression and nociceptive behavior in rats.

Carey LM, Lee WH, Gutierrez T, Kulkarni PM, Thakur GA, Lai YY, Hohmann AG.

Neuroscience. 2017 May 4;349:303-317. doi: 10.1016/j.neuroscience.2017.02.055. Epub 2017 Mar 8.

17.

The chemotherapeutic agent paclitaxel selectively impairs learning while sparing source memory and spatial memory.

Smith AE, Slivicki RA, Hohmann AG, Crystal JD.

Behav Brain Res. 2017 Mar 1;320:48-57. doi: 10.1016/j.bbr.2016.11.042. Epub 2016 Nov 28.

18.

Prophylactic treatment with the tricyclic antidepressant desipramine prevents development of paclitaxel-induced neuropathic pain through activation of endogenous analgesic systems.

Deng L, Lee WH, Xu Z, Makriyannis A, Hohmann AG.

Pharmacol Res. 2016 Dec;114:75-89. doi: 10.1016/j.phrs.2016.10.007. Epub 2016 Oct 20.

19.

A pro-nociceptive phenotype unmasked in mice lacking fatty-acid amide hydrolase.

Carey LM, Slivicki RA, Leishman E, Cornett B, Mackie K, Bradshaw H, Hohmann AG.

Mol Pain. 2016 May 13;12. pii: 1744806916649192. doi: 10.1177/1744806916649192. Print 2016.

20.

Source memory in rats is impaired by an NMDA receptor antagonist but not by PSD95-nNOS protein-protein interaction inhibitors.

Smith AE, Xu Z, Lai YY, Kulkarni PM, Thakur GA, Hohmann AG, Crystal JD.

Behav Brain Res. 2016 May 15;305:23-9. doi: 10.1016/j.bbr.2016.02.021. Epub 2016 Feb 22.

21.

Impact of Genetic Reduction of NMNAT2 on Chemotherapy-Induced Losses in Cell Viability In Vitro and Peripheral Neuropathy In Vivo.

Slivicki RA, Ali YO, Lu HC, Hohmann AG.

PLoS One. 2016 Jan 25;11(1):e0147620. doi: 10.1371/journal.pone.0147620. eCollection 2016.

22.

Small molecule inhibitors of PSD95-nNOS protein-protein interactions as novel analgesics.

Lee WH, Xu Z, Ashpole NM, Hudmon A, Kulkarni PM, Thakur GA, Lai YY, Hohmann AG.

Neuropharmacology. 2015 Oct;97:464-75. doi: 10.1016/j.neuropharm.2015.05.038. Epub 2015 Jun 10.

23.

Tolerance to the antinociceptive effects of chronic morphine requires c-Jun N-terminal kinase.

Marcus DJ, Zee M, Hughes A, Yuill MB, Hohmann AG, Mackie K, Guindon J, Morgan DJ.

Mol Pain. 2015 Jun 12;11:34. doi: 10.1186/s12990-015-0031-4.

24.

CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.

Deng L, Cornett BL, Mackie K, Hohmann AG.

Mol Pharmacol. 2015 Jul;88(1):64-74. doi: 10.1124/mol.115.098483. Epub 2015 Apr 22.

25.

A lipid gate for the peripheral control of pain.

Piomelli D, Hohmann AG, Seybold V, Hammock BD.

J Neurosci. 2014 Nov 12;34(46):15184-91. doi: 10.1523/JNEUROSCI.3475-14.2014. Review.

27.

Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.

Deng L, Guindon J, Cornett BL, Makriyannis A, Mackie K, Hohmann AG.

Biol Psychiatry. 2015 Mar 1;77(5):475-87. doi: 10.1016/j.biopsych.2014.04.009. Epub 2014 Apr 25.

28.

Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery.

Rahn EJ, Deng L, Thakur GA, Vemuri K, Zvonok AM, Lai YY, Makriyannis A, Hohmann AG.

Mol Pain. 2014 Apr 18;10:27. doi: 10.1186/1744-8069-10-27.

29.

A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain.

Lynch ME, Cesar-Rittenberg P, Hohmann AG.

J Pain Symptom Manage. 2014 Jan;47(1):166-73. doi: 10.1016/j.jpainsymman.2013.02.018. Epub 2013 Jun 4.

PMID:
23742737
30.
31.

Source memory in the rat.

Crystal JD, Alford WT, Zhou W, Hohmann AG.

Curr Biol. 2013 Mar 4;23(5):387-91. doi: 10.1016/j.cub.2013.01.023. Epub 2013 Feb 7.

34.

Activation of type 5 metabotropic glutamate receptors and diacylglycerol lipase-α initiates 2-arachidonoylglycerol formation and endocannabinoid-mediated analgesia.

Gregg LC, Jung KM, Spradley JM, Nyilas R, Suplita RL 2nd, Zimmer A, Watanabe M, Mackie K, Katona I, Piomelli D, Hohmann AG.

J Neurosci. 2012 Jul 11;32(28):9457-68. doi: 10.1523/JNEUROSCI.0013-12.2012.

35.

Rats answer an unexpected question after incidental encoding.

Zhou W, Hohmann AG, Crystal JD.

Curr Biol. 2012 Jun 19;22(12):1149-53. doi: 10.1016/j.cub.2012.04.040. Epub 2012 May 24.

37.

Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain.

Gutierrez T, Crystal JD, Zvonok AM, Makriyannis A, Hohmann AG.

Pain. 2011 Sep;152(9):1976-87. doi: 10.1016/j.pain.2011.03.038. Epub 2011 May 8.

38.

The endocannabinoid system and cancer: therapeutic implication.

Guindon J, Hohmann AG.

Br J Pharmacol. 2011 Aug;163(7):1447-63. doi: 10.1111/j.1476-5381.2011.01327.x. Review.

39.

Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects.

Rahn EJ, Thakur GA, Wood JA, Zvonok AM, Makriyannis A, Hohmann AG.

Pharmacol Biochem Behav. 2011 Jun;98(4):493-502. doi: 10.1016/j.pbb.2011.02.024. Epub 2011 Mar 5.

40.

Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain.

Guindon J, Guijarro A, Piomelli D, Hohmann AG.

Br J Pharmacol. 2011 Aug;163(7):1464-78. doi: 10.1111/j.1476-5381.2010.01192.x.

41.

Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism.

Clapper JR, Moreno-Sanz G, Russo R, Guijarro A, Vacondio F, Duranti A, Tontini A, Sanchini S, Sciolino NR, Spradley JM, Hohmann AG, Calignano A, Mor M, Tarzia G, Piomelli D.

Nat Neurosci. 2010 Oct;13(10):1265-70. doi: 10.1038/nn.2632. Epub 2010 Sep 19.

42.
43.

Social isolation and chronic handling alter endocannabinoid signaling and behavioral reactivity to context in adult rats.

Sciolino NR, Bortolato M, Eisenstein SA, Fu J, Oveisi F, Hohmann AG, Piomelli D.

Neuroscience. 2010 Jun 30;168(2):371-86. doi: 10.1016/j.neuroscience.2010.04.007. Epub 2010 Apr 13. Erratum in: Neuroscience. 2011 Jul 28;187:103.

44.

Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation.

Rahn EJ, Zvonok AM, Makriyannis A, Hohmann AG.

AAPS J. 2010 Jun;12(2):147-57. doi: 10.1208/s12248-009-9170-8. Epub 2010 Feb 2.

45.

A role for 2-arachidonoylglycerol and endocannabinoid signaling in the locomotor response to novelty induced by olfactory bulbectomy.

Eisenstein SA, Clapper JR, Holmes PV, Piomelli D, Hohmann AG.

Pharmacol Res. 2010 May;61(5):419-29. doi: 10.1016/j.phrs.2009.12.013. Epub 2010 Jan 5.

46.

The endocannabinoid system and pain.

Guindon J, Hohmann AG.

CNS Neurol Disord Drug Targets. 2009 Dec;8(6):403-21. Review.

47.

Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside.

Rahn EJ, Hohmann AG.

Neurotherapeutics. 2009 Oct;6(4):713-37. doi: 10.1016/j.nurt.2009.08.002. Review.

48.

Endocannabinoid modulation of amphetamine sensitization is disrupted in a rodent model of lesion-induced dopamine dysregulation.

Eisenstein SA, Holmes PV, Hohmann AG.

Synapse. 2009 Nov;63(11):941-50. doi: 10.1002/syn.20679.

49.

Molecular architecture of endocannabinoid signaling at nociceptive synapses mediating analgesia.

Nyilas R, Gregg LC, Mackie K, Watanabe M, Zimmer A, Hohmann AG, Katona I.

Eur J Neurosci. 2009 May;29(10):1964-78. doi: 10.1111/j.1460-9568.2009.06751.x. Epub 2009 May 9.

50.

Targeting CB2 receptors and the endocannabinoid system for the treatment of pain.

Anand P, Whiteside G, Fowler CJ, Hohmann AG.

Brain Res Rev. 2009 Apr;60(1):255-66. doi: 10.1016/j.brainresrev.2008.12.003. Epub 2008 Dec 25. Review.

Supplemental Content

Loading ...
Support Center